Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles

Frontiers in Cellular and Infection Microbiology

Volumn 8, Issue , 2018, Pages

  Furfaro, Lucy L ^a   Payne, Matthew S ^a   Chang, Barbara J ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

alternative treatments; antimicrobial resistance; bacteriophage; clinical trials; phage therapy; regulations

Indexed keywords

BACTERIOLYSIS; BACTERIOPHAGE; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GROWTH, DEVELOPMENT AND AGING; HUMAN; MULTIDRUG RESISTANCE; PHAGE THERAPY; PROCEDURES; STANDARDS; VIROLOGY;

BACTERIOLYSIS; BACTERIOPHAGES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; PHAGE THERAPY;

EID: 85056271139     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2018.00376     Document Type: Review

References (71)

1. Abedon S. T. (2017). Information phage therapy research should report. Pharmaceuticals 10:E43. 10.3390/ph1002004328468287
2. Bassetti M. Poulakou G. Ruppe E. Bouza E. Van Hal S. J. Brink A. (2017). Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach. Intensive Care Med. 43, 1464–1475. 10.1007/s00134-017-4878-x28733718
3. Bertoye A. Gaillard L. Courtieu A. L. (1959). Adapted bacteriophages in the treatment of infections caused by antibiotic-resistant microorganisms. J. Med. Lyon 40, 465–471. 13655000
4. Bolocan A. S. Callanan J. Forde A. Ross P. Hill C. (2016). Phage therapy targeting Escherichia coli-a story with no end? FEMS Microbiol. Lett. 363:fnw256. 10.1093/femsle/fnw25627974392
5. Breidenstein E. B. De La Fuente-Nunez C. Hancock R. E. (2011). Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 19, 419–426. 10.1016/j.tim.2011.04.00521664819
6. Burrowes B. Harper D. R. Anderson J. Mcconville M. Enright M. C. (2011). Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens. Expert Rev. Anti Infect Ther. 9, 775–785. 10.1586/eri.11.9021905786
7. Cao F. Wang X. Wang L. Li Z. Che J. Wang L. et al. (2015). Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed. Res. Int. 2015:752930. 10.1155/2015/75293025879036
8. Cha K. Oh H. K. Jang J. Y. Jo Y. Kim W. K. Ha G. U. et al. (2018). Characterization of two novel bacteriophages infecting multidrug-resistant (MDR) Acinetobacter baumannii and evaluation of their therapeutic efficacy in vivo. Front. Microbiol. 9:696. 10.3389/fmicb.2018.0069629755420
9. Chadha P. Katare O. P. Chhibber S. (2017). Liposome loaded phage cocktail: enhanced therapeutic potential in resolving Klebsiella pneumoniae mediated burn wound infections. Burns 43, 1532–1543. 10.1016/j.burns.2017.03.02928502784
10. Chan B. K. Sistrom M. Wertz J. E. Kortright K. E. Narayan D. Turner P. E. (2016). Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6:26717. 10.1038/srep2671727225966
11. Chan B. K. Turner P. E. Kim S. Mojibian H. R. Elefteriades J. A. Narayan D. (2018). Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol. Med. Public Health 2018, 60–66. 10.1093/emph/eoy00529588855
12. Chang R. Y. Wong J. Mathai A. Morales S. Kutter E. Britton W. et al. (2017). Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection. Eur. J. Pharm. Biopharm. 121, 1–13. 10.1016/j.ejpb.2017.09.00228890220
13. Chang R. Y. K. Chen K. Wang J. Wallin M. Britton W. Morales S. et al. (2018). Proof-of-principle study in a murine lung infection model of antipseudomonal activity of phage PEV20 in a dry-powder formulation. Antimicrob. Agents Chemother. 62:e01714–e01717. 29158280
14. Chhibber S. Nag D. Bansal S. (2013). Inhibiting biofilm formation by Klebsiella pneumoniae B5055 using an iron antagonizing molecule and a bacteriophage. BMC Microbiol. 13:174. 10.1186/1471-2180-13-17423889975
15. Daly A. K. (2007). Individualized drug therapy. Curr Opin Drug Discov Devel 10, 29–36. 17265738
16. De Jonge P. A. Nobrega F. L. Brouns S. J. J. Dutilh B. E. (2018). Molecular and evolutionary determinants of bacteriophage host range. Trends Microbiol. 7:1352. 10.1016/j.tim.2018.08.006
17. De Kraker M. E. Stewardson A. J. Harbarth S. (2016). Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 13:e1002184. 10.1371/journal.pmed.100218427898664
18. Dufour N. Delattre R. Ricard J. D. Debarbieux L. (2017). The lysis of pathogenic Escherichia coli by bacteriophages releases less endotoxin than by beta-lactams. Clin. Infect. Dis. 64, 1582–1588. 10.1093/cid/cix18428329379
19. Edgar B. (2004). The genome of bacteriophage T4: an archeological dig. Genetics 168, 575–582. 15514035
20. Fong S. A. Drilling A. Morales S. Cornet M. E. Woodworth B. A. Fokkens W. J. et al. (2017). Activity of bacteriophages in removing biofilms of Pseudomonas aeruginosa isolates from chronic rhinosinusitis patients. Front. Cell Infect. Microbiol. 7:418. 10.3389/fcimb.2017.0041829018773
21. Forti F. Roach D. R. Cafora M. Pasini M. E. Horner D. S. Fiscarelli E. V. et al. (2018). Design of a broad-range bacteriophage cocktail that reduces Pseudomonas aeruginosa biofilms and treats acute infections in two animal models. Antimicrob. Agents Chemother. 62:e02573–17. 10.1128/AAC.02573-1729555626
22. Garcia-Quintanilla M. Pulido M. R. Lopez-Rojas R. Pachon J. Mcconnell M. J. (2013). Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol. 21, 157–163. 10.1016/j.tim.2012.12.00223317680
23. Ghajavand H. Esfahani B. N. Havaei A. Fazeli H. Jafari R. Moghim S. (2017). Isolation of bacteriophages against multidrug resistant Acinetobacter baumannii. Res. Pharm. Sci. 12, 373–380. 10.4103/1735-5362.21398228974975
24. Gorski A. Miedzybrodzki R. Lobocka M. Glowacka-Rutkowska A. Bednarek A. Borysowski J. et al. (2018). Phage therapy: what have we learned? Viruses 10:E288. 10.3390/v1006028829843391
25. Guo M. Feng C. Ren J. Zhuang X. Zhang Y. Zhu Y. et al. (2017). A novel antimicrobial endolysin, LysPA26, against Pseudomonas aeruginosa. Front. Microbiol. 8:293. 10.3389/fmicb.2017.0029328289407
26. Harper D. R. (2018). Criteria for selecting suitable infectious diseases for phage therapy. Viruses 10:E177. 10.3390/v1004017729621149
27. Huys I. Pirnay J. P. Lavigne R. Jennes S. De Vos D. Casteels M. et al. (2013). Paving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy. EMBO Rep. 14, 951–954. 10.1038/embor.2013.16324136414
28. Keen E. C. (2015). A century of phage research: bacteriophages and the shaping of modern biology. Bioessays 37, 6–9. 10.1002/bies.20140015225521633
29. Krut O. Bekeredjian-Ding I. (2018). Contribution of the immune response to phage therapy. J. Immunol. 200, 3037–3044. 10.4049/jimmunol.170174529685950
30. Kumari S. Harjai K. Chhibber S. (2011). Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by Klebsiella pneumoniae B5055. J. Med. Microbiol. 60, 205–210. 10.1099/jmm.0.018580-020965914
31. Kusradze I. Karumidze N. Rigvava S. Dvalidze T. Katsitadze M. Amiranashvili I. et al. (2016). Characterization and testing the efficiency of Acinetobacter baumannii phage vB-GEC_Ab-M-G7 as an antibacterial agent. Front. Microbiol. 7:1590. 10.3389/fmicb.2016.0159027757110
32. Kutateladze M. (2015). Experience of the eliava institute in bacteriophage therapy. Virol. Sinica 30, 80–81. 10.1007/s12250-014-3557-025662889
33. Kutter E. De Vos D. Gvasalia G. Alavidze Z. Gogokhia L. Kuhl S. et al. (2010). Phage therapy in clinical practice: treatment of human infections. Curr. Pharm. Biotechnol. 11, 69–86. 10.2174/13892011079072540120214609
34. Larpin Y. Oechslin F. Moreillon P. Resch G. Entenza J. M. Mancini S. (2018). In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria. PLoS ONE 13:e0192507. 10.1371/journal.pone.019250729408864
35. Lavergne S. Hamilton T. Biswas B. Kumaraswamy M. Schooley R. T. Wooten D. (2018). Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection. Open Forum Infect. Dis. 5:ofy064. 10.1093/ofid/ofy06429687015
36. Leitner L. Sybesma W. Chanishvili N. Goderdzishvili M. Chkhotua A. Ujmajuridze A. et al. (2017). Bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomized, placebo-controlled, double-blind clinical trial. BMC Urol. 17:90. 10.1186/s12894-017-0283-628950849
37. Liu Y. Mi Z. Niu W. An X. Yuan X. Liu H. et al. (2016). Potential of a lytic bacteriophage to disrupt Acinetobacter baumannii biofilms in vitro. Future Microbiol. 11, 1383–1393. 10.2217/fmb-2016-010427538011
38. Lood R. Winer B. Y. Pelzek A. J. Diez-Martinez R. Thandar M. Euler C. W. et al. (2015). Novel phage lysin capable of killing the multidrug-resistant Gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model. Antimicrob Agents Chemother. 59, 1983–1991. 10.1128/AAC.04641-1425605353
39. Lyczak J. B. Cannon C. L. Pier G. B. (2000). Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect. 2, 1051–1060. 10.1016/S1286-4579(00)01259-410967285
40. Mcconnell M. J. Actis L. Pachón J. (2013). Acinetobacter baumannii: human infections, factors contributing to pathogenesis and animal models. FEMS Microbiol. Rev. 37, 130–155. 10.1111/j.1574-6976.2012.00344.x22568581
41. Miedzybrodzki R. Borysowski J. Weber-Dabrowska B. Fortuna W. Letkiewicz S. Szufnarowski K. et al. (2012). Clinical aspects of phage therapy. Adv. Virus Res. 83, 73–121. 10.1016/B978-0-12-394438-2.00003-722748809
42. Olszak T. Zarnowiec P. Kaca W. Danis-Wlodarczyk K. Augustyniak D. Drevinek P. et al. (2015). In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients. Appl. Microbiol. Biotechnol. 99, 6021–6033. 10.1007/s00253-015-6492-625758956
43. O'neill J. (2014). Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev. Antimicrob. Resist. Available online at: http://amr-review.org/
44. Parracho H. M. Burrowes B. H. Enright M. C. Mcconville M. L. Harper D. R. (2012). The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 6, 279–286. 10.4172/1747-0862.100005022872803
45. Payne R. J. Jansen V. A. (2003). Pharmacokinetic principles of bacteriophage therapy. Clin. Pharmacokinet 42, 315–325. 10.2165/00003088-200342040-0000212648024
46. Pelfrene E. Willebrand E. Cavaleiro Sanches A. Sebris Z. Cavaleri M. (2016). Bacteriophage therapy: a regulatory perspective. J. Antimicrob. Chemother. 71, 2071–2074. 10.1093/jac/dkw08327068400
47. Peng S. Y. You R. I. Lai M. J. Lin N. T. Chen L. K. Chang K. C. (2017). Highly potent antimicrobial modified peptides derived from the Acinetobacter baumannii phage endolysin LysAB2. Sci. Rep. 7:11477. 10.1038/s41598-017-11832-728904355
48. Pirnay J. P. Blasdel B. G. Bretaudeau L. Buckling A. Chanishvili N. Clark J. R. et al. (2015). Quality and safety requirements for sustainable phage therapy products. Pharm. Res. 32, 2173–2179. 10.1007/s11095-014-1617-725585954
49. Pirnay J. P. Verbeken G. Ceyssens P. J. Huys I. De Vos D. Ameloot C. et al. (2018). The magistral phage. Viruses 10:E64. 10.3390/v1002006429415431
50. Regeimbal J. M. Jacobs A. C. Corey B. W. Henry M. S. Thompson M. G. Pavlicek R. L. et al. (2016). Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob. Agents Chemother. 60, 5806–5816. 10.1128/AAC.02877-1527431214
51. Rhoads D. D. Wolcott R. D. Kuskowski M. A. Wolcott B. M. Ward L. S. Sulakvelidze A. (2009). Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J. Wound Care 18, 237–238, 240–233. 10.12968/jowc.2009.18.6.4280119661847
52. Roach D. R. Leung C. Y. Henry M. Morello E. Singh D. Di Santo J. P. et al. (2017). Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 22, 38–47.e34. 10.1016/j.chom.2017.06.01828704651
53. Rossitto M. Fiscarelli E. V. Rosati P. (2018). Challenges and promises for planning future clinical research into bacteriophage therapy against Pseudomonas aeruginosa in cystic Fibrosis. An argumentative review. Front. Microbiol. 9:775. 10.3389/fmicb.2018.0077529780361
54. Sarker S. A. Sultana S. Reuteler G. Moine D. Descombes P. Charton F. et al. (2016). Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine 4, 124–137. 10.1016/j.ebiom.2015.12.02326981577
55. Schooley R. T. Biswas B. Gill J. J. Hernandez-Morales A. Lancaster J. Lessor L. et al. (2017). Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection. Antimicrob Agents Chemother. 61:e00954–17. 10.1128/AAC.00954-1728807909
56. Shiley J. R. Comfort K. K. Robinson J. B. (2017). Immunogenicity and antimicrobial effectiveness of Pseudomonas aeruginosa specific bacteriophage in a human lung in vitro model. Appl. Microbiol. Biotechnol. 101, 7977–7985. 10.1007/s00253-017-8504-128914348
57. Soothill J. (2013). Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections. Expert Rev. Anti Infect Ther. 11, 909–915. 10.1586/14787210.2013.82699024053272
58. Soothill J. S. (1992). Treatment of experimental infections of mice with bacteriophages. J. Med. Microbiol. 37, 258–261. 10.1099/00222615-37-4-2581404324
59. Speck P. Smithyman A. (2016). Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol. Lett. 363:fnv242. 10.1093/femsle/fnv24226691737
60. Stahl F. (1989). The linkage map of phage T4. Genetics 123, 245–248. 2684743
61. Tacconelli E. Carrara E. Savoldi A. Harbarth S. Mendelson M. Monnet D. L. et al. (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 18, 318–327. 10.1016/S1473-3099(17)30753-329276051
62. Thandar M. Lood R. Winer B. Y. Deutsch D. R. Euler C. W. Fischetti V. A. (2016). Novel engineered peptides of a phage lysin aseffective antimicrobials against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 60, 2671–2679. 10.1128/AAC.02972-1526856847
63. Tkhilaishvili T. Di Luca M. Abbandonato G. Maiolo E. M. Klatt A. B. Reuter M. et al. (2018). Real-time assessment of bacteriophage T3-derived antimicrobial activity against planktonic and biofilm-embedded Escherichia coli by isothermal microcalorimetry. Res. Microbiol. [Epub ahead of print].10.1016/j.resmic.2018.05.01029886257
64. Vahedi A. Dallal M. M. S. Douraghi M. Nikkhahi F. Rajabi Z. Yousefi M. et al. (2018). Isolation and identification of specific bacteriophage against enteropathogenic Escherichia coli (EPEC) and in vitro and in vivo characterization of bacteriophage. FEMS Microbiol. Lett. 365:fny136. 10.1093/femsle/fny136
65. Verbeken G. Pirnay J. P. Lavigne R. Jennes S. De Vos D. Casteels M. et al. (2014). Call for a dedicated European legal framework for bacteriophage therapy. Arch. Immunol. Ther. Exp. 62, 117–129. 10.1007/s00005-014-0269-y24500660
66. Villarroel J. Larsen M. V. Kilstrup M. Nielsen M. (2017). Metagenomic analysis of therapeutic PYO phage cocktails from 1997 to 2014. Viruses 9:E328. 10.3390/v911032829099783
67. Waters E. M. Neill D. R. Kaman B. Sahota J. S. Clokie M. R. J. Winstanley C. et al. (2017). Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72:666. 10.1136/thoraxjnl-2016-20926528265031
68. Wright A. Hawkins C. H. Anggard E. E. Harper D. R. (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349–357. 10.1111/j.1749-4486.2009.01973.x19673983
69. Yan G. Liu J. Ma Q. Zhu R. Guo Z. Gao C. et al. (2017). The N-terminal and central domain of colicin A enables phage lysin to lyse Escherichia coli extracellularly. Antonie Van Leeuwenhoek 110, 1627–1635. 10.1007/s10482-017-0912-928730370
70. Yin S. Huang G. Zhang Y. Jiang B. Yang Z. Dong Z. et al. (2017). Phage Abp1 rescues human cells and mice from infection by pan-drug resistant Acinetobacter baumannii. Cell Physiol. Biochem. 44, 2337–2345. 10.1159/00048611729258062
71. Zhou W. Feng Y. Zong Z. (2018). Two new lytic bacteriophages of the myoviridae family against carbapenem-resistant Acinetobacter baumannii. Front. Microbiol. 9:850. 10.3389/fmicb.2018.0085029760690